Abstracts tagged "Biomarkers"

Abstract Number: 1225 • ACR Convergence 2021
Baseline Extracellular Matrix Biomarkers Predict Abatacept Treatment Response in MTX-Naive, ACPA+ Patients with Early RA
Paul Emery¹, Yoshiya Tanaka², Vivian Bykerk³, Clifton Bingham⁴, Tom WJ Huizinga⁵, Gustavo Citera⁶, Chun Wu⁷, Sarah Hu⁷, Peter Schafer⁷, Jinqi Liu⁷, Sean Connolly⁷, Robert Wong⁸ and Roy Fleischmann⁹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Basking Ridge, NJ, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Predictive biomarkers reflecting RA processes and treatment (tmt) efficacy are urgently needed to inform medical options. Markers of bone remodeling and extracellular matrix (ECM)…
Abstract Number: 1423 • ACR Convergence 2021
Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
Melissa Munroe¹, Rufei Lu², Timothy Gross¹, George Tsokos³, Michael Keith⁴, John Harley⁵ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, OUHSC, Oklahoma City, OK, ³BIDMC, Boston, MA, ⁴Inova, Arlington, VA, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: SLE is a chronic autoimmune disease driven by immune dysregulation. We have previously identified patterns of disordered immunity present prior to and concurrent with…
Abstract Number: 1778 • ACR Convergence 2021
The Role of Cathepsin G in Joint Destruction in Patients with Psoriatic Arthritis
Mariela Geneva-Popova¹, Stanislava Popova¹ and Anastas Batalov², ¹Medical University, Faculty of Medicine, Department of Propedeutic of Internal Diseases, Plovdiv, Bulgaria, ²UMHAT KASPELA, Plovdiv, Bulgaria
Background/Purpose: Cathepsin G (CTSG) is a member of the serine protease family. It is stored in primary granules of myeloid cells, dendritic cells, plasma cells,…
Abstract Number: 0338 • ACR Convergence 2021
Serum and Urine Galectin-9, IP-10 and SIGLEC-1 as Biomarkers of Disease Activity in Patients with Systemic Lupus Erythematosus
Safak Mirioglu¹, Suzan Cinar², Omer Uludag³, Erdem Gurel³, Sibel Varelci³, Yasemin Ozluk⁴, Isin Kilicaslan⁴, Yasemin Yalcinkaya⁵, Halil Yazici⁶, Ahmet Gül³, Murat Inanc⁷ and Bahar Esen⁵, ¹Division of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey, ²Department of Immunology, Istanbul University Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkey, ³Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁴Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁶Division of Nephrology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁷Istanbul University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Galectin-9, interferon-inducible protein-10 (IP-10) and sialoadhesin (SIGLEC-1) are proteins associated with interferon signature, and considered as potential biomarkers reflecting disease activity in patients with…
Abstract Number: 0500 • ACR Convergence 2021
Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in the Skin
Monica Yang¹, Vivien Goh², Monica Espinoza³, Yiwei Yuan⁴, Julia Lee⁵, Mary Carns⁶, Dinesh Khanna⁷, Zsuzsanna McMahan⁸, Michael Whitfield⁹ and Monique Hinchcliff¹⁰, ¹University of California San Francisco, San Francisco, CA, ²Northwestern University, Chicago, IL, ³Geisel School of Medicine, Hanover, NH, ⁴Dartmouth College, Hanover, NH, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University Division of Rheumatology, Chicago, IL, ⁷University of Michigan, Ann Arbor, MI, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹Geisel School of Medicine, Lebanon, NH, ¹⁰Yale School of Medicine, Westport, CT
Background/Purpose: Although two subsets in systemic sclerosis (SSc) have been identified based on degree of skin disease, the current classification system, limited vs. diffuse cutaneous,…
Abstract Number: 0928 • ACR Convergence 2021
Filgotinib Treatment Results in Reduction of Inflammatory and Matrix Remodeling Biomarkers Associated with Disease in Patients with Ankylosing Spondylitis
Walter Maksymowych¹, Yuan Tian², Jingting Xu², William Barchuk³, René Galien⁴, Robin Besuyen⁵, Yihua Liu², Vlad Malkov² and Angie Hertz², ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos NV, Romainvulle, France, ⁵Galapagos BV, Leiden, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) – also referred to as radiographic axial spondyloarthritis – is a chronic inflammatory disease that affects the sacroiliac joints and spine.…
Abstract Number: 1231 • ACR Convergence 2021
Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials
Philip Conaghan¹, Sang Hee Park², Mirko Fillbrunn³, Karissa Lozenski², Vadim Khaychuk², Kaleb Michaud⁴, Elyse Swallow³, Henry Lane³, Ha Nguyen³ and Janet Pope⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Bristol Myers Squibb, Princeton, NJ, ³Analysis Group, Inc., Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Western Ontario, London, ON, Canada
Background/Purpose: Biomarkers play an important role in RA and can help guide treatment decisions. Previous studies have suggested differential treatment efficacy of abatacept (ABA) in…
Abstract Number: 1453 • ACR Convergence 2021
Lung Interleukin-33 Is Elevated in Rheumatoid Arthritis-Associated Lung Disease
Rohit Gaurav¹, Ted Mikuls¹, Geoffrey Thiele¹, Bryant England¹, Madison Wolfe¹, Kristina Bailey¹, Amy Nelson¹, Michael Duryee¹, Debra Romberger¹, Dana Ascherman² and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The alarmin interleukin (IL)-33 is a member of the IL-1 cytokine family that is rapidly released from the nucleus of a variety of lung…
Abstract Number: 1789 • ACR Convergence 2021
Prediction of Psoriatic Arthritis in Patients with Psoriasis Using DNA Methylation Profiles
Omar Cruz Correa¹, Remy Pollock¹, Rohan Machhar² and Dafna Gladman³, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) poses an immense clinical burden with significantly increased morbidity and mortality risk compared to psoriasis alone. PsA may develop in 30%…
Abstract Number: 0340 • ACR Convergence 2021
Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis
Huihua Ding¹, Yiwei Shen¹, Min Dai¹, Chandra Mohan² and Nan Shen³, ¹Shanghai JiaoTong University School of Medicine, Shanghai, China (People's Republic), ²University of Houston, Houston, TX, ³Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: There remains unmet needs of non-invasive markers of disease activity, damage, prognosis, and treatment response in lupus nephritis patients. Here, we aim to validate…
Abstract Number: 0502 • ACR Convergence 2021
Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms
Benjamin Hur¹, Matthew Koster¹, Jin Sung Jang¹, Kenneth Warrington² and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota
Background/Purpose: Non-infectious aortitis may be a manifestation of systemic large vessel vasculitis such as giant cell arteritis (GCA) or may be a form of single…
Abstract Number: 0980 • ACR Convergence 2021
Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib
Christina Charles-Schoeman¹, Craig Hyde², Shunjie Guan³, Neil Parikh¹, Jennifer Wang¹, Ani Shahbazian¹, Lori Stockert⁴ and John Andrews⁴, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein-associated enzyme with paraoxonase, lactonase, and arylesterase activities.1 PON1 gene polymorphisms at the Q192R allele (rs662) have been associated…
Abstract Number: 1240 • ACR Convergence 2021
Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs
Fang Cai¹, Thierry Sornasse², Feng Hong³, Heidi Camp⁴, Koji Kato⁵ and Iain McInnes⁶, ¹AbbVie, Redwood City, CA, ²AbbVie Inc, Redwood City, CA, ³AbbVie, Worcester, MA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc, Shinagawa- Ku, Japan, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: In patients with active rheumatoid arthritis (RA) refractory to biologic DMARDs (bDMARD-IR), a phase 3, double-blind and active-controlled study (SELECT-CHOICE) demonstrated that upadacitinib (UPA)…
Abstract Number: 1475 • ACR Convergence 2021
Long Term Compressive Loading Modulates the Extracellular Matrix Response to Growth Factors in Bovine Cartilage Explants
Frederik Gillesberg¹, Amalie Engstrøm¹, Morten Karsdal², Anne-Christine Bay-Jensen³ and Christian S Thudium³, ¹University of Copenhagen, Herlev, Denmark, ²Nordic Bioscience, Herlev, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Mechanical loading of cartilage is an essential part of the function and maintenance of the joint. Despite the apparent importance of continuous mechanical loading,…
Abstract Number: 1816 • ACR Convergence 2021
Treatment of Non-biologic-DMARD-IR PsA Patients with Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional Pathways: Proteomics Analysis of a Phase 3 Study
Thierry Sornasse¹, Jaclyn Anderson², Koji Kato³, Apinya Lertratanakul⁴, Christopher Ritchlin⁵ and Iain McInnes⁶, ¹AbbVie Inc, Redwood City, CA, ²AbbVie Inc, Gurnee, IL, ³AbbVie Inc, Shinagawa- Ku, Japan, ⁴AbbVie Inc., North Chicago, IL, ⁵Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Treatment of non-biologic-DMARD-IR (DMARD-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in improvement in musculoskeletal symptoms,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].